Financial Performance - The company expects a net profit attributable to shareholders of between 600 million and 750 million yuan, a significant turnaround from a loss of 1.363 billion yuan in the same period last year[3] - The net profit is projected to increase by 144.01% to 155.01% compared to the previous year[3] - The company anticipates a profit of 560 million to 710 million yuan after deducting non-recurring gains and losses, compared to a loss of 1.378 billion yuan last year[3] - The basic earnings per share are expected to be between 0.44 yuan and 0.55 yuan, recovering from a loss of 1.01 yuan per share in the previous year[3] Sales and Market Performance - The number of pigs sold reached 3.0285 million, representing a year-on-year increase of 7.55%[5] - The company benefited from rising pig sales prices and decreasing feed raw material costs, leading to a significant reduction in breeding costs and a substantial increase in profits from pig farming[5] - The feed business sales remained stable compared to the previous year, while the market for veterinary biological products faced increasing competition, impacting revenue growth[5] Cost Management and Competition - The company has implemented cost-cutting measures to reduce operating costs amid competitive pressures in the veterinary products market[5] Risks and Uncertainties - Risks include significant fluctuations in pig market prices and potential impacts from diseases such as African swine fever, which could affect operational performance[7] - The financial data provided is preliminary and unaudited, with the final figures to be disclosed in the 2024 annual report[8]
天康生物(002100) - 2024 Q4 - 年度业绩预告